The trial is investigating CT-0508, an anti-HER2 CAR Macrophage, and Phase-1 results have shown that CT-0508 is well tolerated without any dose-limiting toxicities, adverse events, or on-target off-tumor activity. Here, ERBB2 is linked to neoplasm.